Secondary prevention of myocardial infarction in Spain. Prevese study;La prevención secundaria del infarto de miocardio en España. Estudio Prevese

Revista Espanola de Cardiologia

Volumn 50, Issue 6, 1997, Pages 406-415

  De Velasco, José Antonio ^a,b   Cosín, Juan ^a   López Sendón, José Luis ^a   De Teresa, Eduardo ^a   De Oya, Manuel ^a   Carrasco, José Luis ^a   Navarro, Ángel ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Coronary heart disease; Lipid profile; Myocardial infarction; Secondary prevention

Indexed keywords

ARTICLE; CLINICAL TRIAL; HEART INFARCTION; HUMAN; RISK FACTOR; SPAIN;

HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; SPAIN;

EID: 0031159115     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(97)73242-1     Document Type: Article

References (11)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stst Q 1988; 41: 155-178.
2. Tuomiletho J, Kuulasmaa K, Torppa J. WHO MONICA project: geographic variation in mortality from cardiovascular disease. World Health Stat Q 1987; 40: 171-184.
3. Banegas JR, Villar Alvarez F, Martín Moreno JM, Rodríguez Artalejo F, González Enríquez J. Relevancia de la mortalidad por enfermedades del aparato circulatorio en España. Rev Clin Esp 1992; 190: 321-327.
4. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1983; 37: 335-371.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
6. Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242-249.
7. O'Connor GT, Buring JF, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger Jr RS et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 60: 234-244.
8. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1.112-1.129.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1.383-1.389.
10. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996; 75: 334-342.
11. American Heart Association Medical/Scientific Consensus Panel Statement. Circulation 1995; 92: 2-4.